170 related articles for article (PubMed ID: 25155290)
21. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
23. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site.
Subramanian J; Regenbogen T; Nagaraj G; Lane A; Devarakonda S; Zhou G; Govindan R
J Thorac Oncol; 2013 Jul; 8(7):860-5. PubMed ID: 23478543
[TBL] [Abstract][Full Text] [Related]
24. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials.
Jennens RR; Giles GG; Fox RM
Intern Med J; 2006 Apr; 36(4):216-20. PubMed ID: 16640737
[TBL] [Abstract][Full Text] [Related]
25. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
26. Current treatment recommendations for stage III non-small-cell lung carcinoma.
Davis MP; Sause WT
Clin Adv Hematol Oncol; 2003 Oct; 1(10):587-93. PubMed ID: 16258455
[TBL] [Abstract][Full Text] [Related]
27. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.
Nickolich M; Babakoohi S; Fu P; Dowlati A
Clin Lung Cancer; 2014 May; 15(3):207-12. PubMed ID: 24485231
[TBL] [Abstract][Full Text] [Related]
29. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Custodio A; de Castro J
Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
[TBL] [Abstract][Full Text] [Related]
30. Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer.
Taylor MD; LaPar DJ; Isbell JM; Kozower BD; Lau CL; Jones DR
J Thorac Cardiovasc Surg; 2014 Feb; 147(2):738-44; Discussion 744-6. PubMed ID: 24252944
[TBL] [Abstract][Full Text] [Related]
31. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?
Sacher AG; Le LW; Leighl NB; Coate LE
J Thorac Oncol; 2013 Mar; 8(3):366-8. PubMed ID: 23407560
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib for the treatment of non-small-cell lung cancer.
Campbell L; Blackhall F; Thatcher N
Expert Opin Pharmacother; 2010 Jun; 11(8):1343-57. PubMed ID: 20426712
[TBL] [Abstract][Full Text] [Related]
33. [Treatment and prognosis of advanced stage non-small-cell lung cancer].
Chermiti Ben Abdallah F; Ben Ali G; Sadok Boudaya M; Mlika M; Chtourou A; Taktak S; Ben Kheder A
Rev Mal Respir; 2014 Mar; 31(3):214-20. PubMed ID: 24680112
[TBL] [Abstract][Full Text] [Related]
34. Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned.
Faivre-Finn C; Snee M
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):487-9. PubMed ID: 25304944
[No Abstract] [Full Text] [Related]
35. Current readings: Window-of-opportunity trials for thoracic malignancies.
Tsao AS
Semin Thorac Cardiovasc Surg; 2014; 26(4):323-30. PubMed ID: 25837547
[TBL] [Abstract][Full Text] [Related]
36. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman J; Chirieac LR; D'Amico TA; DeCamp MM; Dilling TJ; Dobelbower M; Doebele RC; Govindan R; Gubens MA; Hennon M; Horn L; Komaki R; Lackner RP; Lanuti M; Leal TA; Leisch LJ; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
J Natl Compr Canc Netw; 2017 Apr; 15(4):504-535. PubMed ID: 28404761
[TBL] [Abstract][Full Text] [Related]
37. Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
Brighenti M; Petrelli F; Barni S; Conti B; Sarti E; Ratti M; Panni S; Passalacqua R; Bersanelli M
Eur J Cancer; 2017 Jul; 79():149-151. PubMed ID: 28494405
[TBL] [Abstract][Full Text] [Related]
38. Concurrent chemotherapy and proton beam therapy in NSCLC.
Das M
Lancet Oncol; 2017 Sep; 18(9):e515. PubMed ID: 28757379
[No Abstract] [Full Text] [Related]
39. The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials.
Clarey J; Kao SC; Clarke SJ; Vardy J
Ann Oncol; 2012 May; 23(5):1229-1233. PubMed ID: 21986095
[TBL] [Abstract][Full Text] [Related]
40. Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer.
Ikeda M; Ochibe T; Tohkin M
Ther Innov Regul Sci; 2019 May; 53(3):324-331. PubMed ID: 30089401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
